Drugs / Mesenchymal stem cell
Mesenchymal stem cell
also known as
MSC · bone marrow derived mesenchymal stem cells · BM-MSC · MSCs · Mesenchymal Stromal Cell · BMMSCs · LMSCs · Lomecel-B · +16 more
Trials 58
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00813267 | Dec 2009 → Aug 2011 | osteonecrosis | Jianming Tan | Unknown | No outcome recorded |
| Phase 118 trials · 1 met primary · 1 missed | ||||||
| Phase 1 | NCT05443464 | Jun 2023 → Jun 2024 | acute graft versus host disease | Ossium Health, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05407766 | Aug 2022 → Apr 2024 | anal fistula | Ossium Health, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05095532 | Dec 2021 → Jun 2027 expected | chronic pancreatitis | Medical University of South Carolina | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04236479 | Jul 2020 → Dec 2026 expected | congenital heart disease | Catherine Bollard | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03929120 | Nov 2019 → Jul 2021 | connective tissue disorder, interstitial lung disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02443961 | Apr 2019 → Apr 2020 | bronchopulmonary dysplasia | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
| Phase 1 | NCT03371329 | Dec 2017 → Oct 2020 | intracerebral hemorrhage | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02600130 | Oct 2016 → Sep 2020 | Alzheimer disease | Longeveron Inc. | Completed | Met primary |
| Phase 1 | NCT02490020 | Jan → Dec 2016 | disease related to solid organ transplantation, transplant rejection | Qipeng Sun | Unknown | Missed primary |
| Phase 1 | NCT02327832 | Dec 2014 → Mar 2017 | — | Yamaguchi University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02181712 | Jul 2014 → Aug 2021 | transplant rejection, transplant-related bronchiolitis obliterans | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01759784 | Mar 2014 → Mar 2017 | amyotrophic lateral sclerosis | Royan Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT01775774 | Jul 2013 → Feb 2014 | acute respiratory distress syndrome | Michael A. Matthay | Completed | No outcome recorded |
| Phase 1 | NCT01725698 | Nov 2012 → Dec 2014 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 1 | NCT01440309 | Nov 2011 → Nov 2013 | primary biliary cholangitis | Robert Chunhua Zhao, MD, PhD | Unknown | No outcome recorded |
| Phase 1 | NCT01436058 | Sep 2010 → Sep 2011 | osteoarthritis | Royan Institute | Completed | No outcome recorded |
| Phase 1 | NCT01499056 | Jun 2010 → Feb 2011 | osteoarthritis, hip | Royan Institute | Completed | No outcome recorded |
| Phase 1 | NCT00850187 | Aug 2008 → Jul 2010 | osteoarthritis, knee | Royan Institute | Completed | No outcome recorded |
| Phase 1/218 trials · 1 met primary | ||||||
| Phase 1/2 | NCT05939167 | Dec 2023 → Jul 2027 expected | AIDS | Cell Energy Life Sciences Group Co. LTD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05433298 | May → Nov 2022 | COVID-19, pneumonia | Paulo Brofman | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04565665 | Jul 2020 → Oct 2027 expected | COVID-19, acute respiratory distress syndrome, cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03460795 | Jun 2020 → Mar 2025 | cirrhosis of liver | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03863002 | Oct 2019 → Oct 2021 | liver failure | Tianjin Weikai Bioeng., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03460223 | Apr 2018 → Mar 2020 | renal fibrosis | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03525418 | Feb 2018 → Jun 2024 | hypoplastic left heart syndrome | Longeveron Inc. | Unknown | Met primary |
| Phase 1/2 | NCT03484741 | Apr 2017 → Nov 2018 | type 1 diabetes mellitus | Van Hanh General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02116634 | May 2015 → May 2017 | amyotrophic lateral sclerosis | Alzahra Hospital, Iran | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01877759 | Dec 2013 → Dec 2014 | cirrhosis of liver | Chaitanya Hospital, Pune | Unknown | No outcome recorded |
| Phase 1/2 | NCT01844063 | Jul 2013 → Jan 2016 | liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01446640 | Oct 2011 → Jun 2013 | spinal cord injury | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 1/2 | NCT01446614 | Oct 2011 → Jun 2013 | Parkinson disease | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 1/2 | NCT01305694 | Feb 2011 → Jun 2012 | aplastic anemia | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 1/2 | NCT01322789 | Sep 2008 → Nov 2015 | type 1 diabetes mellitus | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 1/2 | NCT00659620 | May 2008 | chronic transplant rejection | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00659217 | May 2008 → May 2010 | lupus nephritis | Organ Transplant Institute, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT00646724 | Jan 2008 → Jan 2012 | type 1 diabetes mellitus | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 216 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07544537 | Sep 2024 → Jan 2026 overdue | erectile dysfunction | National Scientific Medical Center, Kazakhstan | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02587572 | Dec 2023 | metabolic disease | Longeveron Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04925024 | Jun 2021 → Jun 2026 overdue | hypoplastic left heart syndrome | Longeveron Inc. | Active not recruiting | Missed primary |
| Phase 2 | NCT02814864 | Apr 2021 → Apr 2022 | radiation cystitis, radiation proctitis | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT03362424 | Nov 2020 → Dec 2023 | disease of the tendon, rotator cuff syndrome | University of Sao Paulo | Suspended | No outcome recorded |
| Phase 2 | NCT04501354 | Aug → Dec 2020 | osteoporosis | Ahmad Jabir Rahyussalim | Unknown | No outcome recorded |
| Phase 2 | NCT03164083 | Nov 2019 → Aug 2020 | osteoarthritis | SCARM Institute, Tabriz, Iran | Withdrawn | No outcome recorded |
| Phase 2 | NCT03917797 | Apr 2019 → Dec 2024 | lupus nephritis, systemic lupus erythematosus | Universidad de los Andes, Chile | Unknown | No outcome recorded |
| Phase 2 | NCT04499105 | Jul 2017 → Dec 2020 | intervertebral disk degenerative disorder | Ahmad Jabir Rahyussalim | Unknown | No outcome recorded |
| Phase 2 | NCT03169231 | Jul 2017 → Sep 2021 | — | Longeveron Inc. | Completed | Met primary |
| Phase 2 | NCT04493918 | May 2017 → Dec 2020 | tuberculosis, spinal | Ahmad Jabir Rahyussalim | Unknown | No outcome recorded |
| Phase 2 | NCT02112500 | Feb 2014 → Dec 2016 | adult acute respiratory distress syndrome | Asan Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02140528 | Aug 2013 → Mar 2016 | — | Royan Institute | Completed | No outcome recorded |
| Phase 2 | NCT01504464 | Oct 2012 → Sep 2015 | osteoarthritis, knee | Royan Institute | Completed | No outcome recorded |
| Phase 2 | NCT01741090 | Sep 2009 → Jun 2013 | alcoholic liver cirrhosis | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT00972660 | Sep 2009 → Dec 2015 | chronic graft versus host disease | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04545307 | Nov → Dec 2019 | chronic apical periodontitis, dental pulp necrosis | Universidad Central de Venezuela | Completed | No outcome recorded |
| Phase 2/3 | NCT02448849 | Jun 2015 → Apr 2017 | disease of bone structure | Royan Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT01526850 | Feb 2012 → Dec 2013 | chronic graft versus host disease | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02414295 | Aug 2013 → Aug 2014 | Klinefelter syndrome, azoospermia | Man Clinic for Andrology, Male Infertility and Sexual Dysfunction | Completed | No outcome recorded |
| — | NCT01499459 | Jun 2008 → Jul 2012 | cirrhosis of liver | University of Health Sciences Gulhane Faculty of Medicine | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT04629105 Comparator | Jul 2020 → Jun 2024 | COVID-19, acute respiratory distress syndrome | Longeveron Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02266394 Comparator | Oct 2014 → Sep 2020 | chronic kidney disease, ischemic disease, renal artery disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00955669 Comparator | Aug 2009 → Aug 2010 | — | Third Military Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT01849887 Comparator | Jan 2016 | ischemic stroke | University of California, Irvine | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00644410 Comparator | Sep 2008 → Mar 2015 | congestive heart failure | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 1/2 | NCT00260338 Comparator | Dec 2005 → Jul 2009 | coronary artery disorder, myocardial ischemia | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT02513238 Comparator | Aug 2015 → Apr 2017 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2/3 | NCT01392105 Comparator | Mar 2007 → May 2010 | acute myocardial infarction | Yonsei University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 50
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | Longeveron Inc. | Results Longeveron to Participate in Three Longevity/Aging Investment Conferences longeveron.com ↗
New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxiv |
| 2026-09-16 | Longeveron Inc. | Results Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) longeveron.com ↗
The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12. |
| 2026-07-13 | Longeveron Inc. | Results Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease longeveron.com ↗
In this new post-hoc exploratory analysis of CLEAR-MIND results, the anti-inflammatory effect was observed to be most prominent in the hippocampus, temporal lobe, and other AD-associated areas and correlated (Spearman) with both increased brain volume and improved cognitive and quality of life scores. |
| 2026-02-25 | Longeveron Inc. | Results Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell longeveron.com ↗
The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. |
| 2025-12-01 | Longeveron Inc. | Results Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) longeveron.com ↗
Reduction in hippocampal neuroinflammation, measured using MRI assessed free water, correlated strongly with preservation of hippocampal volume and with clinical outcomes |
| 2025-05-07 | NextCell Pharma Ab | Results Study published in Nature Medicine shows promising results in Alzheimer’s disease – supports the development of ProTrans at NextCell nextcellpharma.com ↗
The treatment led to improved cognitive symptoms, reduced neuroinflammation, and slower brain atrophy, with no reported serious adverse events. |
| 2025-04-15 | BioCardia, Inc. | Results BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial biocardia.com ↗
Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. |
| 2025-03-11 | Longeveron Inc. | Results Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease longeveron.com ↗
Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s disease |
| 2025-02-18 | Longeveron Inc. | Regulatory Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™ longeveron.com ↗
today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization approved “laromestrocel” for the non-proprietary name of the Company’s cellular therapy Lomecel-B™ . |
| 2024-10-29 | Longeveron Inc. | Results Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) longeveron.com ↗
Lomecel-B™ capacity to inhibit MMP14 correlates with improved clinical and biomarker outcomes in mild AD |
| 2024-10-27 | Longeveron Inc. | Results Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting longeveron.com ↗ |
| 2024-07-28 | Longeveron Inc. | Results Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC) longeveron.com ↗
Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s Disease |
| 2024-07-17 | Longeveron Inc. | Regulatory Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease longeveron.com ↗ |
| 2024-07-10 | Longeveron Inc. | Regulatory Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease longeveron.com ↗
today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease |
| 2023-12-20 | Longeveron Inc. | Results Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease longeveron.com ↗
Additional analysis of cognitive function and daily living data consistently showed favorable results with Lomecel-B™ over placebo in a dose-response fashion, with administration of Lomecel-B™ associated with slowing and in some cases improving certain measurements of cognitive function (MoCA, MMSE). |
| 2023-12-18 | Personalized Stem Cells, Inc. | Results PSC Knee Osteoarthritis Stem Cell Research Results personalizedstemcells.com ↗
Personalized Stem Cells (PSC) has completed the first ever FDA-approved clinical trial of GMP lab manufactured ASCs for patients with knee osteoarthritis. |
| 2023-11-11 | Longeveron Inc. | Results Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association longeveron.com ↗
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients |
| 2023-10-05 | Longeveron Inc. | Results Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease longeveron.com ↗
today announced positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease. |
| 2023-05-09 | Longeveron Inc. | Results Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome longeveron.com ↗
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B TM during their Stage 2 surgery. |
| 2023-05-02 | Corestemchemon, Inc. | Results "중간엽줄기세포, 루게릭병 치료제 희망” 코아스템켐온 ‘뉴로나타-알’ 주목 corestemchemon.com ↗
중간엽줄기세포 치료가 생존기간을 4년가량 연장 시킨 데 영향을 미친 것으로 볼 수 있다. |
| 2023-01-19 | Longeveron Inc. | Results Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal longeveron.com ↗
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the publication of the full results from the Company’s ELPIS I trial of Lomecel-B TM for hypoplastic left heart syndrome (HLHS) in the European Heart Journal Open . |
| 2022-08-31 | Longeveron Inc. | Regulatory U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants longeveron.com ↗ |
| 2022-08-28 | Cynata Therapeutics Limited | Results Preclinical study in coronary artery disease published cynata.com ↗ |
| 2022-03-31 | Longeveron Inc. | Results Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association longeveron.com ↗
The trial met its primary endpoint, demonstrating that Lomecel-B was well tolerated in this patient population. |
| 2022-03-16 | Ossium Health, Inc. | Regulatory Ossium Health Announces FDA Clearance of its Investigational New Drug Application for Treatment of Perianal Fistulizing Crohn’s Disease ossiumhealth.com ↗
Ossium Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OSSM-001, a mesenchymal stem cell (MSC) product, for the treatment of refractory perianal fistulas in patients with Crohn’s disease. |
| 2021-12-06 | Longeveron Inc. | Regulatory Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS) longeveron.com ↗ |
| 2021-11-18 | Longeveron Inc. | Regulatory U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition longeveron.com ↗ |
| 2021-09-29 | Longeveron Inc. | Results Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity longeveron.com ↗
Biomarker analysis, which is considered exploratory in this trial, revealed that administration of Lomecel-B was associated with a statistically significant reduction in serum levels of soluble TIE-2 (sTIE-2) in a dose-dependent fashion at Day 270 compared to placebo. |
| 2021-09-27 | Cynata Therapeutics Limited | Results CYP Preclinical Heart Attack Study Published in Cytotherapy cynata.com ↗
The paper, entitled “ Pluripotent stem cell derived mesenchymal stromal cells improve cardiac function and vascularity after myocardial infarction”, has been published online on the Cytotherapy website, and will appear in a print edition in the near future. |
| 2021-09-09 | Longeveron Inc. | Results Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients longeveron.com ↗
Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment. |
| 2021-08-13 | Longeveron Inc. | Results Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results longeveron.com ↗
Today we announced encouraging top-line results from our Phase 2b Aging Frailty trial evaluating the safety and efficacy of four different doses of Lomecel-B compared to placebo in Aging Frailty subjects. |
| 2021-08-13 | Longeveron Inc. | Results Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty longeveron.com ↗
Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) at Day 180 |
| 2020-09-14 | Cynata Therapeutics Limited | Results Cynata Clinical Trial Results Published in Nature Medicine cynata.com ↗
Overall Response rate by Day 100 was 87% (13/15 patients showed an improvement in GvHD severity by at least one grade compared to baseline) |
| 2020-06-01 | Longeveron Inc. | Regulatory Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron’s Stem Cells longeveron.com ↗ |
| 2020-04-16 | Cynata Therapeutics Limited | Results Cynata MSCs beneficial in preclinical ARDS study cynata.com ↗
Preclinical Study Showing Beneficial Effects of Cymerus™ MSCs in Acute Respiratory Distress Syndrome Accepted for Publication in Leading Peer-Reviewed Journal |
| 2019-02-19 | Longeveron Inc. | Results Longeveron LLC will discuss the company's latest clinical research of its stem cell treatments for Aging Frailty at the International Conference on Frailty & Sarcopenia Research, to be held February 20-22 at the Eden Roc Hotel on Miami Beach longeveron.com ↗
Trial participants, with an average age of 76, showed marked improvement in physical performance, lung function and reduction of inflammation, all significant biomarkers of Frailty. |
| 2019-02-06 | Cynata Therapeutics Limited | Results Study of CYP-001 Published in Leading Peer Review Journal cynata.com ↗
Cymerus MSCs reduce GvHD severity and significantly prolong survival in a humanised mouse model of GVHD. |
| 2018-08-29 | Cynata Therapeutics Limited | Results Cynata GvHD Trial Meets all Safety & Efficacy Endpoints cynata.com ↗
Cynata Therapeutics Limited (ASX: CYP) is pleased to announce that CYP-001, its lead Cymerus™ mesenchymal stem cell (MSC) product candidate, met all clinical endpoints in a Phase 1 trial for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). |
| 2018-06-20 | Cynata Therapeutics Limited | Results Positive 28-day Clinical Trial Data in Cohort B cynata.com ↗
Higher dose of CYP-001 administered in Cohort B elicited a faster response than the lower dose in Cohort A. |
| 2018-02-26 | Cynata Therapeutics Limited | Results Excellent Data from Final Preliminary Evaluation Period cynata.com ↗
Overall Response rate by Day 100 was 100% (all eight participants showed an improvement in the severity of GvHD by at least one grade compared to baseline) |
| 2018-01-23 | Longeveron Inc. | Results Longeveron Shares Promising State of Regenerative Medicine Research with Experts at the FDA, NIH and Other Leading Organizations at National Conference longeveron.com ↗
A single injection of the allogeneic mesenchymal stem cells, in fact, was associated with significant gains in functional capacity in both Phase I and Phase II studies Longeveron published in The Journals of Gerontology in 2017. |
| 2018-01-22 | Cynata Therapeutics Limited | Results Encouraging Early Data-Cynata Clinical Trial Proceeds cynata.com ↗
All eight participants in Cohort A (lower dose cohort) have demonstrated at least a Partial Response (defined as an improvement in the severity of GvHD by at least one grade compared to baseline) |
| 2017-10-23 | Longeveron Inc. | Results University Of Miami Miller School of Medicine: Stem Cell Studies Build Momentum toward Therapy for Age-Associated Frailty longeveron.com ↗
Now Phase II randomized, placebo-controlled trial findings have verified their initial study, boosting the potential for this stem cell therapy to reverse or forestall the symptoms of frailty. |
| 2017-10-20 | Longeveron Inc. | Results Miami Herald: Stem cell infusions improved health in frail elderly, UM researchers say longeveron.com ↗
The first phase of Hare’s study, which involved 15 people, showed that stem cell infusions were safe for patients. |
| 2017-10-17 | Longeveron Inc. | Results Longeveron Pioneering Development of Stem Cell Therapies for Aging Frailty longeveron.com ↗
Participants showed marked improvement in physical performance, lung function and inflammation biomarkers, all major aspects of frailty, with no serious adverse events attributable to the product. |
| 2017-05-15 | Longeveron Inc. | Results Longeveron Announces Publication of Phase 1 Safety and Efficacy Trial Results for Allogeneic Stem Cell Treatment in Frailty Patients longeveron.com ↗
Longeveron LLC, a leading regenerative medicine company developing innovative therapies for age-related diseases, announced the publication of Phase 1 safety, tolerability and efficacy data of its proprietary allogeneic mesenchymal stem cell (MSC) product in patients with Aging Frailty. |
| 2017-05-10 | Longeveron Inc. | Results Longeveron Begins Enrollment of Second Cohort of Phase 1 Trial of Allogeneic Mesenchymal Stem Cells to Treat Alzheimer’s Disease Patients longeveron.com ↗
The first five patients in our program have so far shown that the use of LMSCs in Alzheimer’s disease is safe. |
| 2016-12-15 | Cynata Therapeutics Limited | Regulatory Cynata's Clinical Study Approved in Austrralia cynata.com ↗
Cynata Therapeutics Limited (ASX: CYP), has received approval from the Royal Adelaide Hospital HREC for its Phase 1 clinical trial of CYP-001 in patients with steroid-resistant acute GvHD. |
| 2016-12-12 | Cynata Therapeutics Limited | Regulatory Cynata Receives NHS HRA Approval for Clinical Study cynata.com ↗ |
| 2016-01-11 | Cynata Therapeutics Limited | Results Cynata CLI Study Published in Peer Reviewed Journal cynata.com ↗
This marks the first published in vivo study of Cynata’s proprietary Cymerus MSCs and demonstrates the beneficial effect of MSCs manufactured using Cynata’s unique technology in treating CLI. |
All press releases naming this drug 78 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 76 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mesenchymal stem cell | “In particular, mesenchymal stem cell (MSC) transplantation has been applicated in the clinic for treat several human diseases such as liver injury and liver fibrosis displayed...” NCT03460795 ↗37“mesenchymal stem cell (MSC) transplantation has been applicated in the clinic for treat several human diseases” NCT03460223 ↗ “intraventricular injection of mesenchymal stem cell by stereotaxis” NCT01759784 ↗ “bone marrow derived cultured MSC (mesenchymal stem cell)” NCT03371329 ↗ “intra articular inection of mesenchymal stem cell” NCT01499056 ↗ |
| Known as | Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01775774 ↗ |
| Known as | BM-MSC | “We first compared long-term clinical outcomes in treating critical limb ischemia (CLI) and foot ulcer in patients with diabetes between autologous bone marrow mesenchymal stem...” PMID 30917698 ↗ Mar 20195“The investigators will evaluate safety and efficacy of percutaneous implantation of autologous BM-MSC (bone marrow -derived mesenchymal stromal cell) in combination with PL...” NCT02448849 ↗ “autologous bone marrow-derived mesenchymal stem cells (BM-MSC)” NCT03484741 ↗ |
| Known as | BMD-MSCs | “Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)” NCT03929120 ↗ |
| Known as | BMMSCs | “combination of bone marrow-derived mesenchymal stem cells (BM-MSCs), hydroxyapatite (HA) granules, bone morphogenetic protein-2 (BMP-2), and internal fixation for treating CSDs.” PMID 30747273 ↗ Feb 20192“cultured autologous bone marrow derived mesenchymal stem cells (BM-MSCs)” NCT01436058 ↗ “autologous bone-marrow derived mesenchymal stromal cells (BMMSCs)” PMID 24211066 ↗ Oct 2013 |
| Known as | BMSC | “Autologous Bone marrow-derived Mesenchymal Stem Cells (BMSC)” NCT07544537 ↗ |
| Known as | bone marrow -derived mesenchymal stromal cell | “The investigators will evaluate safety and efficacy of percutaneous implantation of autologous BM-MSC (bone marrow -derived mesenchymal stromal cell) in combination with PL...” NCT02448849 ↗ |
| Known as | bone marrow derived mesenchymal stem cells | “The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.” NCT02448849 ↗ |
| Known as | bone marrow derived mesenchymal stromal/stem cell | “Percutaneous implantation of autologous bone marrow derived mesenchymal stromal/stem cell in combination with PL will be done in 30 patients with tibia nonunion.” NCT02448849 ↗ |
| Known as | Bone Marrow Mesenchymal stem cells | “autologous transplantation of Bone Marrow Mesenchymal stem cells (MSCs) mixed with collagen I scaffold” NCT00850187 ↗ |
| Known as | hMSCs | “Human bone marrow-derived mesenchymal stem (stromal) cells (hMSCs) improve survival in mouse models of acute respiratory distress syndrome (ARDS)” PMID 24891325 ↗ Jun 2014 |
| Known as | human MSCs | “a phase 1/2 trial of bone marrow-derived human MSCs for moderate-severe ARDS.” PMID 25593740 ↗ Jul 2014 |
| Known as | laromestrocel | “We conducted a randomized, dose-finding clinical trial to test whether human bone marrow-derived allogeneic mesenchymal stem cells (MSCs; laromestrocel) improve physical...” PMID 41747733 ↗ Feb 2026 |
| Known as | LMSCs | “This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for...” NCT02600130 ↗2“evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome” NCT02587572 ↗ “Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)” NCT03169231 ↗ |
| Known as | Lomecel-B | “This study is designed to assess the safety, tolerability, and efficacy of Lomecel-B (formerly LMSCs) as an adjunct therapy to the standard stage II (BDCPA) surgical...” NCT03525418 ↗2“Each subject will be intravenously infused with 100 million Lomecel-B (formerly LMSCs) or placebo on Day 0.” NCT04629105 ↗ |
| Known as | Longeveron Mesenchymal Stem Cells | “evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome” NCT02587572 ↗ |
| Known as | mesenchymal stem cells | “mesenchymal stem cells (MSCs) are collected from autologous bone marrow mononuclear cells” NCT03484741 ↗1“allogeneic, bone marrow (BM) derived mesenchymal stem cells (MSC)” NCT03371329 ↗ |
| Known as | mesenchymal stem/stromal cells | “Human bone marrow-derived mesenchymal stem (stromal) cells (hMSCs) improve survival in mouse models of acute respiratory distress syndrome (ARDS)” PMID 24891325 ↗ Jun 20141“human allogeneic bone marrow-derived mesenchymal stem/stromal cells” PMID 38114796 ↗ Dec 2023 |
| Known as | Mesenchymal Stromal Cell | “autologous bone-marrow derived mesenchymal stromal cells (BMMSCs)” PMID 24211066 ↗ Oct 2013 |
| Known as | mesenchymal stromal cells | “mesenchymal stromal cells (MSCs) from a related donor” PMID 23731760 ↗ Jul 2013 |
| Known as | MSC | “Mesenchymal stem cells (MSC) are grown from a person's own fat tissue (obtained as a fat biopsy) and infused back into the patient's own kidney.” NCT02266394 ↗13“Effectiveness and Safety of Mesenchymal Stem Cell (MSC) Implantation on Degenerative Discus Disease Patients” NCT04499105 ↗ “mesenchymal stem cell (MSC) had an effect to prevent rejection and DGF after renal transplantation” NCT02490020 ↗ “Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties.” NCT00813267 ↗ “Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties.” NCT00659620 ↗ “Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties.” NCT00659217 ↗ “autologous mesenchymal stem cell (MSC) transplantation” NCT01499459 ↗ “Mesenchymal Stromal Cell (MSC) injections” NCT02814864 ↗ “Experimental:Mesenchymal stem cell(MSC).” NCT00972660 ↗ “Mesenchymal Stem Cell (MSC) therapy” NCT02443961 ↗ |
| Known as | MSCs | “bone marrow (BM)-derived mesenchymal stem cells (MSCs) transplanted in patients with OA of the knee, ankle, or hip” PMID 26058927 ↗ Jun 20155“Mesenchymal stem cells (MSCs) with potent anti-inflammatory, regenerative and immune-modulatory properties” PMID 29514693 ↗ Mar 2018 “delivery of mesenchymal stem/stromal cells (MSCs) has already been translated to human subjects with RAS” PMID 34183258 ↗ Jun 2021 “autologous transplantation of Bone Marrow Mesenchymal stem cells (MSCs) mixed with collagen I scaffold” NCT00850187 ↗ “Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties.” NCT00813267 ↗ “mesenchymal stromal cells (MSCs) from a related donor” PMID 23731760 ↗ Jul 2013 |
| Known as | OSSM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05443464 ↗ |
| Known as | stem cell transplantation | “intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation” NCT03164083 ↗ |
| Known as | UC-MSCs | “human umbilical-cord-derived MSCs (UC-MSCs) via the peripheral vein before renal transplantation” PMID 29514693 ↗ Mar 2018 |
| Action | Inhibit | “MSCs can fully suppress T cell function” NCT01305694 ↗ |
| Modality | Cell therapy | “autologous mesenchymal stem cell therapy” NCT00260338 ↗ |
| Route | Other | “direct intramyocardial injections of autologous isolated and expanded mesenchymal stem cells.” NCT00260338 ↗ |